TLDR:
- Cardurion Pharmaceuticals raised $260M in Series B financing for cardiovascular disease treatment.
- Human Interest secured $242M for 401(k) plans, valuing the company at $1.3B.
The week’s top 10 funding rounds in the U.S. saw $100M+ investments in various sectors. Biotech company Cardurion Pharmaceuticals led the way with a $260 million Series B financing, focusing on cardiovascular disease therapeutics. Human Interest, a financial services company, received $242 million for 401(k) plan offerings, reaching a valuation of $1.3 billion. Other notable rounds included Tekion in automotive ($200M), Saronic in defense ($175M), and Scorpion Therapeutics in biotech ($150M). Additionally, Aven in fintech ($142M), NGM Biopharmaceuticals in biotech ($122M), Kandji in information technology ($100M), Halo Industries in semiconductor ($80M), and DreamBig Semiconductor in semiconductor ($75M) secured significant investments. The global market also saw big deals, with Sydney-based Symphony raising approximately $201M in renewable energy. Overall, these funding rounds reflect the diverse investment landscape in the U.S. across various industries.
